Foresite Capital Fund IV, L.P.

13D and 13G Filings

13D/G filings: 13G on 4 securities
Location: San Francisco, CA
CIK: 0001704131
Form D filings: 1 filing
All SEC filings: View on sec.gov

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
Lyell Immunopharma, Inc. 13G/A Amendment 4 LYEL · 55083R203	LYEL	55083R203	2.7%	653,328	13G/A Amendment 4	8/14/2026 Event 6/30/2026
Foresite Capital Fund IV, L.P.			0%	0
Foresite Capital Management IV, LLC			0%	0
Foresite Capital Fund V, L.P.			1.9%	476,386
Foresite Capital Management V, LLC			1.9%	476,386
Foresite Capital Opportunity Fund V, L.P.			0.7%	176,942
Foresite Capital Opportunity Management V, LLC			0.7%	176,942
James B. Tananbaum			2.7%	653,328
Eikon Therapeutics, Inc. 13G EIKN · 282564103	EIKN	282564103	7.7%	4,148,519	13G	2/11/2026 Event 2/4/2026
Foresite Capital Fund IV, L.P.			3.6%	1,960,774
Foresite Capital Management IV, LLC			3.6%	1,960,774
Foresite Capital Fund V, L.P.			2.5%	1,353,168
Foresite Capital Management V, LLC			2.5%	1,353,168
Foresite Capital Opportunity Fund V, L.P.			0.8%	425,852
Foresite Capital Opportunity Management V, LLC			0.8%	425,852
Foresite Capital VI-A, LLC			0.8%	408,725
Foresite Capital VI-A Management, LLC			0.8%	408,725
James B. Tananbaum			7.7%	4,148,519
Lyell Immunopharma, Inc. 13G/A Amendment 3 LYEL · 55083R203	LYEL	55083R203	7.6%	1,454,616	13G/A Amendment 3	11/14/2025 Event 9/30/2025
Foresite Capital Fund IV, L.P.			4.2%	800,339
Foresite Capital Management IV, LLC			4.2%	800,339
Foresite Capital Fund V, L.P.			2.5%	477,078
Foresite Capital Management V, LLC			2.5%	477,078
Foresite Capital Opportunity Fund V, L.P.			0.9%	177,199
Foresite Capital Opportunity Management V, LLC			0.9%	177,199
James B. Tananbaum			7.6%	1,454,616
Maze Therapeutics, Inc. 13G/A Amendment 1 MAZE · 578784100	MAZE	578784100	1.4%	608,948	13G/A Amendment 1	11/14/2025 Event 9/30/2025
Foresite Capital Fund IV, L.P.			1.2%	522,657
Foresite Capital Management IV, LLC			1.2%	522,657
Foresite Capital Fund V, L.P.			0.2%	86,291
Foresite Capital Management V, LLC			0.2%	86,291
James Tananbaum			1.4%	608,948
Lyell Immunopharma, Inc. 13G/A Amendment 2 LYEL · 55083R104	LYEL	55083R104	9.2%	27,161,892	13G/A Amendment 2	5/15/2025 Event 3/31/2025
Foresite Capital Fund IV, L.P.			5.4%	16,007,999
Foresite Capital Management IV, LLC			5.4%	16,007,999
Foresite Capital Fund V, L.P.			2.8%	8,133,047
Foresite Capital Management V, LLC			2.8%	8,133,047
Foresite Capital Opportunity Fund V, L.P.			1.0%	3,020,846
Foresite Capital Opportunity Management V, LLC			1.0%	3,020,846
James B. Tananbaum			9.2%	27,161,892
Lyell Immunopharma, Inc. 13G/A Amendment 1 LYEL · 55083R104	LYEL	55083R104	6.7%	19,478,893	13G/A Amendment 1	2/14/2025 Event 12/31/2024
Foresite Capital Fund IV, L.P.			2.9%	8,325,000
Foresite Capital Management IV, LLC			2.9%	8,325,000
Foresite Capital Fund V, L.P.			2.8%	8,133,047
Foresite Capital Management V, LLC			2.8%	8,133,047
Foresite Capital Opportunity Fund V, L.P.			1.0%	3,020,846
Foresite Capital Opportunity Management V, LLC			1.0%	3,020,846
James Tananbaum			6.7%	19,478,893
Maze Therapeutics, Inc. 13G MAZE · 578784100	MAZE	578784100	5.6%	2,457,108	13G	2/7/2025 Event 1/31/2025
Foresite Capital Fund IV, L.P.			4.8%	2,111,917
Foresite Capital Management IV, LLC			4.8%	2,111,917
Foresite Capital Fund V, L.P.			0.8%	345,191
Foresite Capital Management V, LLC			0.8%	345,191
James Tananbaum			5.6%	2,457,108
Maze Therapeutics, Inc. 13G MAZE · 578784100	MAZE	578784100	5.6%	2,457,108	13G	2/7/2025 Event 1/31/2025
Foresite Capital Fund IV, L.P.			4.8%	2,111,917
Foresite Capital Management IV, LLC			4.8%	2,111,917
Foresite Capital Fund V, L.P.			0.8%	345,191
Foresite Capital Management V, LLC			0.8%	345,191
James Tananbaum			5.6%	2,457,108

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.